Nurix Therapeutics (NRIX)
Market Price (4/19/2026): $17.7 | Market Cap: $1.9 BilSector: Health Care | Industry: Biotechnology
Nurix Therapeutics (NRIX)
Market Price (4/19/2026): $17.7Market Cap: $1.9 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -25% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Protein Degradation, Show more. | Weak multi-year price returns2Y Excs Rtn is -34% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.55, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -315 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -439% Weak revenue growthRev Chg QQuarterly Revenue Change % is -66% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 54% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -363%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -379% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20% Key risksNRIX key risks include [1] a complete dependence on positive clinical outcomes for its specific drug candidates, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -25% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Protein Degradation, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -34% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.55, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -315 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -439% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -66% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 54% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -363%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -379% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20% |
| Key risksNRIX key risks include [1] a complete dependence on positive clinical outcomes for its specific drug candidates, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Weak Q1 2026 Financial Performance and Increased Burn Rate.
Nurix Therapeutics reported a significant decrease in Q1 2026 revenue, which fell to $6 million, representing a 66.1% year-over-year decline. Concurrently, the company's operating loss worsened to $92 million in Q1 2026, compared to a $63 million loss in Q1 2025. Research and development expenses increased to $84.1 million for the three months ended February 28, 2026, up from $69.7 million in the prior year period, primarily due to accelerating enrollment in the Phase 2 bexobrutideg trial and enabling Phase 3 trials. This increased cash burn contributed to a reduction in cash, cash equivalents, and marketable securities to $540.7 million as of February 28, 2026, down from $592.9 million as of November 30, 2025.
2. Advancement of Lead Program into a Head-to-Head Phase 3 Trial Against an Established Competitor.
The company's lead candidate, bexobrutideg, is proceeding to a global randomized confirmatory Phase 3 trial (DAYBreak CLL-306) by mid-2026, where it will be directly compared against pirtobrutinib, an already approved non-covalent BTK inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia. While a necessary step for regulatory approval, this direct head-to-head comparison in a competitive hematology market introduces clinical and commercial execution risks, which can be a source of investor apprehension.
Show more
Stock Movement Drivers
Fundamental Drivers
The -7.7% change in NRIX stock from 12/31/2025 to 4/18/2026 was primarily driven by a -23.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 18.97 | 17.51 | -7.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 84 | 72 | -14.2% |
| P/S Multiple | 19.1 | 26.9 | 40.8% |
| Shares Outstanding (Mil) | 84 | 110 | -23.5% |
| Cumulative Contribution | -7.7% |
Market Drivers
12/31/2025 to 4/18/2026| Return | Correlation | |
|---|---|---|
| NRIX | -7.7% | |
| Market (SPY) | -5.4% | 48.0% |
| Sector (XLV) | -3.9% | 31.9% |
Fundamental Drivers
The 89.5% change in NRIX stock from 9/30/2025 to 4/18/2026 was primarily driven by a 206.2% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.24 | 17.51 | 89.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 88 | 72 | -18.8% |
| P/S Multiple | 8.8 | 26.9 | 206.2% |
| Shares Outstanding (Mil) | 84 | 110 | -23.8% |
| Cumulative Contribution | 89.5% |
Market Drivers
9/30/2025 to 4/18/2026| Return | Correlation | |
|---|---|---|
| NRIX | 89.5% | |
| Market (SPY) | -2.9% | 31.8% |
| Sector (XLV) | 7.4% | 19.9% |
Fundamental Drivers
The 47.4% change in NRIX stock from 3/31/2025 to 4/18/2026 was primarily driven by a 57.4% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.88 | 17.51 | 47.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 55 | 72 | 31.6% |
| P/S Multiple | 17.1 | 26.9 | 57.4% |
| Shares Outstanding (Mil) | 78 | 110 | -28.8% |
| Cumulative Contribution | 47.4% |
Market Drivers
3/31/2025 to 4/18/2026| Return | Correlation | |
|---|---|---|
| NRIX | 47.4% | |
| Market (SPY) | 16.3% | 33.4% |
| Sector (XLV) | 3.3% | 36.1% |
Fundamental Drivers
The 97.2% change in NRIX stock from 3/31/2023 to 4/18/2026 was primarily driven by a 116.6% change in the company's P/S Multiple.| (LTM values as of) | 3312023 | 4182026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.88 | 17.51 | 97.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 39 | 72 | 85.8% |
| P/S Multiple | 12.4 | 26.9 | 116.6% |
| Shares Outstanding (Mil) | 54 | 110 | -51.0% |
| Cumulative Contribution | 97.2% |
Market Drivers
3/31/2023 to 4/18/2026| Return | Correlation | |
|---|---|---|
| NRIX | 97.2% | |
| Market (SPY) | 63.3% | 32.3% |
| Sector (XLV) | 20.3% | 28.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NRIX Return | -12% | -62% | -6% | 83% | 1% | -12% | -49% |
| Peers Return | -1% | -49% | -7% | 1% | 27% | 17% | -29% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 3% | 87% |
Monthly Win Rates [3] | |||||||
| NRIX Win Rate | 50% | 17% | 42% | 58% | 42% | 25% | |
| Peers Win Rate | 56% | 47% | 33% | 47% | 57% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| NRIX Max Drawdown | -31% | -73% | -61% | -25% | -56% | -24% | |
| Peers Max Drawdown | -25% | -59% | -58% | -33% | -51% | -9% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ARVN, KYMR, GLUE, BMY, CCCC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/17/2026 (YTD)
How Low Can It Go
| Event | NRIX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -91.5% | -25.4% |
| % Gain to Breakeven | 1080.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to ARVN, KYMR, GLUE, BMY, CCCC
In The Past
Nurix Therapeutics's stock fell -91.5% during the 2022 Inflation Shock from a high on 1/19/2021. A -91.5% loss requires a 1080.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Nurix Therapeutics (NRIX)
AI Analysis | Feedback
Here are 1-3 brief analogies for Nurix Therapeutics (NRIX):
- An early-stage Genentech or Amgen, focused on discovering novel small molecule drugs for cancer and immune disorders.
- Like Vertex Pharmaceuticals, but instead of focusing on cystic fibrosis, Nurix is developing specialized small molecule drugs for various cancers and autoimmune diseases.
- A biotech innovator that partners with pharmaceutical giants like Gilead and Sanofi to develop cutting-edge therapies for cancer and immune diseases.
AI Analysis | Feedback
- NX-2127: An orally available BTK degrader for relapsed or refractory B-cell malignancies.
- NX-5948: An orally bioavailable BTK degrader targeting relapsed or refractory B-cell malignancies and autoimmune diseases.
- NX-1607: An orally available CBL-B inhibitor developed for immuno-oncology indications.
- NX-0255: A CBL-B inhibitor designed for ex vivo use to enhance adoptive T-cell therapy.
- DeTIL-0255: A therapy undergoing Phase 1 clinical trials for gynecologic cancers, including ovarian, endometrial, and cervical cancer.
AI Analysis | Feedback
Nurix Therapeutics (NRIX) sells primarily to other companies through strategic collaboration agreements. Its major customers are:
- Gilead Sciences, Inc. (Symbol: GILD)
- Sanofi S.A. (Symbol: SNY)
AI Analysis | Feedback
nullAI Analysis | Feedback
Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer, and Board Director
Arthur T. Sands has served as Chief Executive Officer and a member of Nurix's board of directors since September 2014. He also holds the title of President. Prior to joining Nurix, Dr. Sands co-founded Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) in 1995 and served as its President, Chief Executive Officer, and a board director until July 2014. At Lexicon, he played a pivotal role in evolving the company from a research-stage entity to a drug development company, fostering numerous alliances that generated over $450 million in revenue. Dr. Sands also spearheaded Nurix's successful initial public offering (IPO) in 2020. He holds a B.A. from Yale University and earned his M.D. and Ph.D. in Cell Biology from Baylor College of Medicine.
Hans van Houte Chief Financial Officer
Hans van Houte has served as Chief Financial Officer of Nurix since June 2020, having led the company's finance team since 2015. Before his tenure at Nurix, Mr. van Houte held senior finance positions at Vertex Pharmaceuticals, where he contributed to scaling the financial and accounting organization after its IPO. He also served as Vice President of Finance and Operations at Trubion Pharmaceuticals, Inc., participating in the team that took Trubion public in October 2006. Additionally, Mr. van Houte was a managing partner at Bionation LLC, a financial consulting firm, and acted as CFO for several new biotechnology companies that received investments from Third Rock Ventures and The Column Group. He earned his B.S. in Business Administration, Finance and Accounting from Babson College.
Gwenn M. Hansen, Ph.D. Chief Scientific Officer
Gwenn M. Hansen serves as Nurix Therapeutics' Chief Scientific Officer since June 2020, overseeing the company's discovery efforts, including the development of its DNA-encoded library technology. Dr. Hansen joined Nurix in 2015. Her previous experience includes serving as an Associate Professor at Baylor College of Medicine's Center for Drug Discovery and holding senior discovery roles at Lexicon Pharmaceuticals.
Christine Ring, Ph.D., J.D. Chief Legal Officer and Corporate Secretary
Christine Ring was appointed Chief Legal Officer of Nurix Therapeutics in 2019, where she is responsible for all aspects of the company's legal strategy, corporate governance, and compliance. Dr. Ring has a background that includes serving as General Counsel at Oncoceutics and holding legal leadership positions at Cohera Medical and Amylin Pharmaceuticals. She possesses both a Ph.D. and a J.D., which enable her to bridge scientific innovations with legal frameworks.
Jason Kantor, Ph.D. Chief Business Officer
Jason Kantor has served as Nurix's Chief Business Officer since October 2023, and held senior finance and business strategy roles since joining the company in July 2020. Prior to joining Nurix, Dr. Kantor worked as a Senior Biopharma Analyst at Artisan Partners, where he covered industry trends for both large and small-cap biotech and pharma companies globally. He initially joined Nurix in 2019 as VP of Research, following his leadership of discovery teams at Novartis Institutes for Biomedical Research. Dr. Kantor holds a Ph.D. in Pharmacology from the University of Michigan.
AI Analysis | Feedback
The key risks to Nurix Therapeutics include the inherent uncertainties and potential for failure in clinical trials and regulatory approval, intense competition within its target markets, and the need for ongoing capital to fund operations.- Clinical Trial Failure and Regulatory Risk: As a biopharmaceutical company with several drug candidates in various stages of development, Nurix Therapeutics faces significant risk that its product candidates, such as NX-2127, NX-5948, NX-1607, NX-0255, and DeTIL-0255, may not successfully complete clinical trials or receive necessary regulatory approvals. Unfavorable results, including lack of efficacy or the emergence of unexpected adverse events, could severely impact the company's prospects and stock price. For example, Nurix previously experienced a partial clinical hold for its NX-2127 Phase 1 trial. Regulatory delays or additional requirements from agencies like the FDA can also hinder or prevent drug approval.
- Competition: Nurix operates in highly competitive therapeutic areas, including cancer and immune disorders. The company faces fierce competition from other biopharmaceutical firms, including those developing targeted protein degradation (TPD) therapies, such as Arvinas, Kymera Therapeutics, and C4 Therapeutics, as well as established pharmaceutical companies like Eli Lilly (with Pirtobrutinib) and BeiGene. Competitors may develop more effective, safer, or more affordable treatments, or bring products to market faster, potentially limiting Nurix's market share and profitability.
- Financial Sustainability and Need for Future Capital: Nurix Therapeutics is a clinical-stage company that currently generates net losses and significantly invests in research and development, as it does not yet have approved products generating commercial sales. The company is actively consuming its cash reserves to fund its pipeline development. Sustained negative earnings could necessitate future capital raises through equity offerings or debt financing, which may dilute the ownership of existing shareholders. While Nurix has strategic collaborations that provide some funding, its long-term financial health depends on its ability to bring successful products to market.
AI Analysis | Feedback
nullAI Analysis | Feedback
Nurix Therapeutics (NRIX) Addressable Markets
Nurix Therapeutics' pipeline targets several significant addressable markets across cancer and immune disorders:
- NX-2127 (BTK degrader for relapsed or refractory B-cell malignancies):
- The global B-cell lymphoma market was valued at approximately USD 5.08 billion in 2024 and is projected to reach USD 10 billion by 2034.
- The U.S. B-cell lymphoma market was valued at USD 1.39 billion in 2024 and is projected to reach USD 2.78 billion by 2034.
- The diffuse large B-cell lymphoma (DLBCL) market across the 7MM (United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan) is expected to grow from USD 5.286 billion in 2025 to USD 16.562 billion by 2034.
- The global Bruton's tyrosine kinase (BTK) inhibitor market, which includes BTK degraders, was valued at USD 10.4 billion in 2025 and is projected to grow to USD 32.7 billion by 2035.
- The U.S. BTK inhibitor market was valued at USD 3.8 billion in 2025.
- NX-5948 (BTK degrader for relapsed or refractory B-cell malignancies and autoimmune diseases):
- For B-cell malignancies, refer to the market sizes for NX-2127 above.
- The global autoimmune disease treatment market was valued at USD 109.53 billion in 2025 and is projected to reach USD 132.964 billion by 2033.
- The U.S. autoimmune disease treatment market accounted for approximately 20.35% of the global market in 2025.
- NX-1607 (CBL-B inhibitor for immuno-oncology indications) & NX-0255 (CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy):
- The global Immuno-Oncology (IO) market was estimated at USD 54.35 billion in 2025 and is projected to reach approximately USD 435.70 billion by 2035.
- North America accounted for 31.27% of the global immuno-oncology market share in 2024.
- The U.S. immuno-oncology market held 89.23% market share in North America in 2024.
- DeTIL-0255 (for gynecologic cancers, including ovarian, endometrial, and cervical cancer):
- The global gynecological cancer drugs market is projected to grow from USD 18.59 billion in 2025 to approximately USD 31.02 billion by 2035.
- North America holds approximately 45% of the global gynecological cancer drug market share.
- The global ovarian cancer market was estimated at USD 3.5 billion in 2023 and is projected to reach USD 6.5 billion by 2032. Another estimate places the global ovarian cancer market at USD 31.64 billion by 2033.
- The U.S. ovarian cancer drugs market is evaluated at USD 1.30 billion in 2025 and is projected to be worth around USD 2.57 billion by 2035.
- The global endometrial cancer market is projected to grow from USD 32.0 billion in 2025 to USD 53.7 billion by 2035.
- The U.S. endometrial cancer treatment market is estimated to be valued at USD 11.3 billion in 2025 and is anticipated to reach USD 17.6 billion by 2035.
- The global cervical cancer treatment market size was valued at approximately USD 8.2 billion in 2023 and is estimated to grow to USD 13.1 billion by 2032.
- The U.S. cervical cancer market size was nearly USD 530 million in 2023.
AI Analysis | Feedback
Nurix Therapeutics (NRIX) is positioned for future revenue growth over the next 2-3 years, driven primarily by the advancement of its pipeline of targeted protein degradation medicines and structured collaboration agreements. Key expected drivers include:
-
Progression and Potential Commercialization of Bexobrutideg (NX-5948) in B-cell Malignancies: Nurix's lead wholly-owned asset, bexobrutideg (NX-5948), is a significant revenue driver. The company initiated the DAYBreak™ pivotal Phase 2 single-arm study in the fourth quarter of 2025 for relapsed or refractory Chronic Lymphocytic Leukemia (CLL). Furthermore, plans are underway to commence a global randomized confirmatory Phase 3 trial (DAYBreak CLL-306) in the first half of 2026 to support full approval. Positive clinical data in CLL and Waldenström Macroglobulinemia (WM), along with U.S. FDA Fast Track Designation and European Medicines Agency (EMA) PRIME designation for CLL, suggest an accelerated path to market, which could generate product sales or licensing revenue within the next 2-3 years.
-
Milestone Payments and Future Royalties from Sanofi Collaborations: Nurix benefits from strategic collaboration agreements with Sanofi. Sanofi exercised its option in June 2025 to exclusively license Nurix's STAT6 program, including the development candidate NX-3911, which resulted in a $15 million license extension fee. Additionally, in April 2025, Sanofi exclusively licensed an undisclosed Nurix program targeting a transcription factor for autoimmune diseases, also triggering a $15 million license extension fee. Nurix remains eligible for substantial development, regulatory, and commercial milestone payments, potentially up to $465 million per licensed program, along with future royalties on sales. The advancement of these partnered programs will continue to generate significant revenue through milestone achievements.
-
Milestone Payments and Future Royalties from Gilead Sciences Collaboration: The collaboration with Gilead Sciences for the IRAK4 degrader, GS-6791 (formerly NX-0479), is another key revenue driver. Nurix received a $5 million clinical milestone payment under this collaboration in the second quarter of 2025. GS-6791 is in clinical development for inflammatory diseases, and its continued progression through clinical stages by Gilead is expected to trigger further milestone payments and potential future royalties on commercial sales.
-
Expansion of Bexobrutideg (NX-5948) into Autoimmune and Inflammatory Indications: Beyond oncology, Nurix plans to expand the development of bexobrutideg into autoimmune and inflammatory diseases, targeting an Investigational New Drug (IND) submission for new indications in 2026. This strategic expansion opens up new, potentially large, market opportunities that could drive future revenue growth either through direct commercialization efforts or new strategic partnerships in these therapeutic areas.
AI Analysis | Feedback
Share Issuance
- Nurix Therapeutics' basic shares outstanding increased from $0.075 billion in February 2021 to $0.338 billion in November 2025.
- The number of shares outstanding increased by 29.12% in one year.
- In Q4 2025, there was an issuance of common stock around $234.8 million, contributing to net financing of approximately $236.0 million for that quarter.
Inbound Investments
- Nurix Therapeutics has strategic collaboration agreements with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates.
- These collaborations provide revenue streams through milestone payments and potential royalties.
- In the three months ended May 31, 2025, Nurix reported revenue of $44.1 million, including $30 million from Sanofi for license extensions and a $5 million clinical milestone from Gilead.
Capital Expenditures
- In the last 12 months, capital expenditures were -$14.00 million.
- Capital expenditures in the most recent quarter (Q4 2025) totaled -$5.13 million.
- Nurix Therapeutics, Inc. invested $5.1 million in capital expenditures in Q4 2025, an increase of 89.3% from the prior quarter, funding long-term assets and infrastructure.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to NRIX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 18.65 |
| Mkt Cap | 1.8 |
| Rev LTM | 98 |
| Op Inc LTM | -111 |
| FCF LTM | -167 |
| FCF 3Y Avg | -138 |
| CFO LTM | -166 |
| CFO 3Y Avg | -133 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 0.4% |
| Rev Chg 3Y Avg | 13.1% |
| Rev Chg Q | -63.7% |
| QoQ Delta Rev Chg LTM | -12.4% |
| Op Inc Chg LTM | 22.0% |
| Op Inc Chg 3Y Avg | 9.5% |
| Op Mgn LTM | -167.9% |
| Op Mgn 3Y Avg | -347.5% |
| QoQ Delta Op Mgn LTM | -30.5% |
| CFO/Rev LTM | -189.4% |
| CFO/Rev 3Y Avg | -265.0% |
| FCF/Rev LTM | -190.4% |
| FCF/Rev 3Y Avg | -279.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.8 |
| P/S | 11.6 |
| P/Op Inc | -6.1 |
| P/EBIT | -6.1 |
| P/E | -7.7 |
| P/CFO | -5.4 |
| Total Yield | -7.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -10.9% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 11.1% |
| 3M Rtn | 0.6% |
| 6M Rtn | 43.8% |
| 12M Rtn | 102.3% |
| 3Y Rtn | 23.2% |
| 1M Excs Rtn | 2.1% |
| 3M Excs Rtn | -2.5% |
| 6M Excs Rtn | 33.4% |
| 12M Excs Rtn | 79.8% |
| 3Y Excs Rtn | -27.7% |
Price Behavior
| Market Price | $17.51 | |
| Market Cap ($ Bil) | 1.7 | |
| First Trading Date | 07/24/2020 | |
| Distance from 52W High | -18.4% | |
| 50 Days | 200 Days | |
| DMA Price | $15.72 | $13.89 |
| DMA Trend | up | down |
| Distance from DMA | 11.4% | 26.1% |
| 3M | 1YR | |
| Volatility | 49.9% | 64.0% |
| Downside Capture | 0.98 | 0.59 |
| Upside Capture | 239.32 | 153.66 |
| Correlation (SPY) | 51.9% | 29.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.94 | 1.94 | 1.84 | 1.69 | 1.18 | 1.55 |
| Up Beta | 2.40 | 2.92 | 4.43 | 3.05 | 0.84 | 1.16 |
| Down Beta | 0.62 | 0.69 | 1.24 | 1.39 | 1.36 | 1.69 |
| Up Capture | 371% | 257% | 133% | 303% | 182% | 598% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 10 | 16 | 26 | 59 | 111 | 349 |
| Down Capture | 168% | 192% | 175% | 87% | 123% | 111% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 11 | 25 | 36 | 65 | 137 | 394 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NRIX | |
|---|---|---|---|---|
| NRIX | 79.9% | 63.9% | 1.17 | - |
| Sector ETF (XLV) | 9.6% | 16.0% | 0.39 | 29.5% |
| Equity (SPY) | 21.1% | 12.9% | 1.32 | 29.8% |
| Gold (GLD) | 50.9% | 27.5% | 1.49 | 0.8% |
| Commodities (DBC) | 25.2% | 16.2% | 1.40 | -4.7% |
| Real Estate (VNQ) | 17.5% | 13.7% | 0.93 | 26.1% |
| Bitcoin (BTCUSD) | -7.8% | 42.6% | -0.08 | 22.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NRIX | |
|---|---|---|---|---|
| NRIX | -7.9% | 73.9% | 0.21 | - |
| Sector ETF (XLV) | 6.4% | 14.6% | 0.25 | 29.6% |
| Equity (SPY) | 10.8% | 17.1% | 0.49 | 34.6% |
| Gold (GLD) | 22.6% | 17.8% | 1.04 | 5.2% |
| Commodities (DBC) | 11.6% | 18.8% | 0.51 | 2.6% |
| Real Estate (VNQ) | 4.4% | 18.8% | 0.14 | 35.2% |
| Bitcoin (BTCUSD) | 5.2% | 56.5% | 0.31 | 17.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NRIX | |
|---|---|---|---|---|
| NRIX | -0.8% | 80.6% | 0.34 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 26.6% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 31.4% |
| Gold (GLD) | 14.3% | 15.9% | 0.75 | 6.1% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | 4.1% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 29.9% |
| Bitcoin (BTCUSD) | 68.4% | 66.9% | 1.07 | 17.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/8/2026 | -4.6% | -0.3% | |
| 1/28/2026 | -1.6% | -7.4% | -10.6% |
| 10/9/2025 | -10.1% | -7.6% | 13.4% |
| 7/9/2025 | -3.9% | -5.8% | -23.6% |
| 4/8/2025 | 3.7% | 6.0% | 4.1% |
| 1/13/2025 | 4.2% | 4.9% | -6.1% |
| 10/11/2024 | 6.5% | 6.0% | 19.1% |
| 7/11/2024 | 8.1% | -4.0% | -5.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 9 | 10 |
| # Negative | 8 | 9 | 7 |
| Median Positive | 4.0% | 4.9% | 18.5% |
| Median Negative | -3.1% | -6.4% | -10.6% |
| Max Positive | 14.5% | 23.9% | 31.9% |
| Max Negative | -10.1% | -12.2% | -34.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 02/28/2026 | 04/08/2026 | 10-Q |
| 11/30/2025 | 01/28/2026 | 10-K |
| 08/31/2025 | 10/09/2025 | 10-Q |
| 05/31/2025 | 07/09/2025 | 10-Q |
| 02/28/2025 | 04/08/2025 | 10-Q |
| 11/30/2024 | 01/28/2025 | 10-K |
| 08/31/2024 | 10/11/2024 | 10-Q |
| 05/31/2024 | 07/11/2024 | 10-Q |
| 02/29/2024 | 04/10/2024 | 10-Q |
| 11/30/2023 | 02/15/2024 | 10-K |
| 08/31/2023 | 10/12/2023 | 10-Q |
| 05/31/2023 | 07/13/2023 | 10-Q |
| 02/28/2023 | 04/13/2023 | 10-Q |
| 11/30/2022 | 02/09/2023 | 10-K |
| 08/31/2022 | 10/06/2022 | 10-Q |
| 05/31/2022 | 07/07/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ring, Christine | Chief Legal Officer | Direct | Sell | 12182025 | 17.90 | 3,760 | 67,314 | 911,196 | Form |
| 2 | Ring, Christine | Chief Legal Officer | Direct | Sell | 11242025 | 17.07 | 37,600 | 641,697 | 868,629 | Form |
| 3 | Van, Houte Hans | Chief Financial Officer | Direct | Sell | 11032025 | 12.56 | 6,284 | 78,931 | 472,182 | Form |
| 4 | Van, Houte Hans | Chief Financial Officer | Direct | Sell | 10302025 | 12.80 | 3,130 | 40,054 | 561,468 | Form |
| 5 | Ring, Christine | Chief Legal Officer | Direct | Sell | 10302025 | 12.80 | 3,644 | 46,631 | 651,314 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.